The KEYNOTE-355 results extend the benefits to the advanced breast cancer setting.
KEYNOTE 355 PEMBROLIZUMAB PLUS
The combination of pembrolizumab plus chemotherapy was granted Breakthrough Therapy designation by the FDA for the neoadjuvant treatment of patients with high-risk, early-stage triple-negative breast cancer. Numerous trials in the neoadjuvant and adjuvant settings have shown the benefits of pembrolizumab as monotherapy and in combination with chemotherapy in PD-L1–positive triple-negative breast cancer. Food and Drug Administration (FDA) for the treatment of patients with locally recurrent, unresectable, or metastatic triple-negative breast cancer whose tumors express PD-L1 ,” she stated. Based on the progression-free survival results from KEYNOTE-355, the combination of pembrolizumab and chemotherapy was granted accelerated approval by the U.S. “These findings provide further support for the addition of pembrolizumab to standard chemotherapy for first-line metastatic triple-negative breast cancer. Rugo presented additional endpoints from KEYNOTE-355 at the 2020 San Antonio Breast Cancer Symposium. “A subgroup analysis showed that pembrolizumab plus chemotherapy improved progression-free survival regardless of the chemotherapy partner.” Dr. Rugo, MD, Professor and Medical Director of Breast Oncology, University of California San Francisco. A trend toward improved progression-free survival was observed with PD-L1 enrichment,” said lead author Hope S.
“Pembrolizumab plus chemotherapy achieved a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone for first-line treatment of PD-L1–positive metastatic triple-negative breast cancer. 1 Progression-free survival was significantly improved with pembrolizumab plus chemotherapy in PD-L1–positive triple-negative breast cancer (ie, combined positive score ≥ 10) regardless of the chemotherapy regimen used in the trial. 387(3):217-226, 2022.Pembrolizumab plus chemotherapy improved progression-free survival vs chemotherapy alone as first-line treatment of advanced or metastatic triple-negative breast cancer, according to the results of KEYNOTE-355. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. * Statistically significant difference between the 2 treatment groups References (nanoparticle albumin-bound paclitaxel, paclitaxel, or gemcitabine–carboplatin) (capecitabine, eribulin, gemcitabine, or vinorelbine) Objective Response Rate-Percent who Responded to Treatment Table note: Objective response rates (percent of people who responded to treatment) and overall survival show data for women with triple negative breast cancers that were PD-L1-positive, defined as a combined positive score (CPS) of 10 or more. Study selection criteria: Randomized clinical trials with 100 or more participants with metastatic triple negative breast cancer. Learn more about pembrolizumab, including its side effects. All metastatic triple negative breast cancers are tested to learn if they are PD-L1-positive.Ĭompared to chemotherapy alone, pembrolizumab in combination with chemotherapy may give people with metastatic PD-L1-positive triple negative breast cancers more time before the cancer spreads. Pembrolizumab in combination with chemotherapy is used to treat metastatic triple negative breast cancers that are programmed cell death ligand 1-positive (PD-L1-positive).
Introduction: Pembrolizumab is a checkpoint inhibitor immunotherapy drug used to treat some metastatic breast cancers. However, to get the most out of the tables, it’s important to understand some key concepts. Summary tables are a useful way to look at the science behind many breast cancer guidelines and recommendations. This summary table contains detailed information about research studies. Research table: Pembrolizumab (Keytruda) for metastatic breast cancer treatment
0 kommentar(er)
